SG11202011366SA - Heterocondensed pyridones compounds and their use as idh inhibitors - Google Patents

Heterocondensed pyridones compounds and their use as idh inhibitors

Info

Publication number
SG11202011366SA
SG11202011366SA SG11202011366SA SG11202011366SA SG11202011366SA SG 11202011366S A SG11202011366S A SG 11202011366SA SG 11202011366S A SG11202011366S A SG 11202011366SA SG 11202011366S A SG11202011366S A SG 11202011366SA SG 11202011366S A SG11202011366S A SG 11202011366SA
Authority
SG
Singapore
Prior art keywords
heterocondensed
pyridones
compounds
idh inhibitors
idh
Prior art date
Application number
SG11202011366SA
Inventor
Ms Elena Casale
Mr Francesco Casuscelli
Ms Teresa Disingrini
Ms Paola Magnaghi
Ms Beatrice Malgesini
Ms Ilaria Motto
Mr Stefano Nuvoloni
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of SG11202011366SA publication Critical patent/SG11202011366SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202011366SA 2018-05-21 2019-05-16 Heterocondensed pyridones compounds and their use as idh inhibitors SG11202011366SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18173430 2018-05-21
PCT/EP2019/062605 WO2019224096A1 (en) 2018-05-21 2019-05-16 Heterocondensed pyridones compounds and their use as idh inhibitors

Publications (1)

Publication Number Publication Date
SG11202011366SA true SG11202011366SA (en) 2020-12-30

Family

ID=62222436

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011366SA SG11202011366SA (en) 2018-05-21 2019-05-16 Heterocondensed pyridones compounds and their use as idh inhibitors

Country Status (16)

Country Link
US (1) US20210206759A1 (en)
EP (1) EP3797107B1 (en)
JP (1) JP7304896B2 (en)
KR (1) KR20210013154A (en)
CN (1) CN112469719B (en)
AU (1) AU2019273599B2 (en)
BR (1) BR112020023736A2 (en)
CA (1) CA3100448A1 (en)
DK (1) DK3797107T3 (en)
EA (1) EA202092767A1 (en)
ES (1) ES2929406T3 (en)
HU (1) HUE060654T2 (en)
MX (1) MX2020012499A (en)
PL (1) PL3797107T3 (en)
SG (1) SG11202011366SA (en)
WO (1) WO2019224096A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115038700A (en) * 2019-11-08 2022-09-09 内尔维亚诺医疗科学公司 Gem disubstituted heterocyclic compounds and their use as IDH inhibitors
EP4065578A1 (en) 2019-11-26 2022-10-05 Theravance Biopharma R&D IP, LLC Fused pyrimidine pyridinone compounds as jak inhibitors
CN115768775A (en) * 2020-06-28 2023-03-07 微境生物医药科技(上海)有限公司 IDH mutant inhibitor and application thereof
CN114685487B (en) * 2020-12-27 2024-04-19 上海凌达生物医药有限公司 Pyrimidine heterocyclic compounds, preparation method and application
WO2023178130A1 (en) * 2022-03-16 2023-09-21 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions, and therapeutic applications

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001509805A (en) * 1997-02-05 2001-07-24 ワーナー−ランバート・コンパニー Pyrido [2,3-D] pyrimidine and 4-aminopyrimidine as cell growth inhibitors
CZ20022521A3 (en) * 2000-01-27 2003-02-12 Warner-Lambert Company Pyridopyrimidinone derivatives for treating neurodegenerative diseases
JP2004083587A (en) * 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd Medicinal composition
DK1685131T3 (en) 2003-11-13 2007-07-09 Hoffmann La Roche Hydroxyalkyl-substituted pyrido-7-pyrimidin-7-ones
CA2624965A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k.alpha.
BRPI0617159B8 (en) 2005-10-07 2021-05-25 Exelixis Inc pi3ka inhibitor pyridopyrimidinone compounds, compositions containing them, and preparation process
AU2007284562B2 (en) * 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
AP2015008707A0 (en) 2013-03-14 2015-09-30 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
US10294206B2 (en) 2015-04-21 2019-05-21 Forma Tm2, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
EP3328866B1 (en) 2015-07-27 2019-10-30 Eli Lilly and Company 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors

Also Published As

Publication number Publication date
JP7304896B2 (en) 2023-07-07
MX2020012499A (en) 2021-02-15
BR112020023736A2 (en) 2021-02-09
AU2019273599A1 (en) 2021-01-14
ES2929406T3 (en) 2022-11-29
DK3797107T3 (en) 2022-11-07
CN112469719A (en) 2021-03-09
KR20210013154A (en) 2021-02-03
JP2021525247A (en) 2021-09-24
EP3797107B1 (en) 2022-08-10
EP3797107A1 (en) 2021-03-31
AU2019273599A2 (en) 2021-01-21
US20210206759A1 (en) 2021-07-08
AU2019273599B2 (en) 2023-12-14
EA202092767A1 (en) 2021-04-13
PL3797107T3 (en) 2022-12-05
WO2019224096A1 (en) 2019-11-28
CA3100448A1 (en) 2019-11-28
CN112469719B (en) 2024-01-23
HUE060654T2 (en) 2023-04-28

Similar Documents

Publication Publication Date Title
IL277079A (en) Cartyrin compositions and methods for use
EP3230234A4 (en) Nitrification inhibitor compositions and methods for preparing the same
EP3250035A4 (en) Compounds and their use as bace1 inhibitors
SG11202011366SA (en) Heterocondensed pyridones compounds and their use as idh inhibitors
ZA201704300B (en) Nitrification inhibitor compositions and methods for preparing the same
IL280809B (en) Novel compositions, their use, and methods for their formation
PL3621694T3 (en) Lrrc33 inhibitors and use thereof
HK1254661A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
HK1250028A1 (en) 2-phenyl-6-imidazolyl-pyridine-4-carboxamide derivatives and their use as eaat3 inhibitors
EP3724194C0 (en) Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
EP3191447A4 (en) S-imino-s-oxo iminothiazine compounds as bace inhibitors, compositions, and their use
GB201614961D0 (en) Compounds and compositions for use
PT3268356T (en) Heterocyclic compounds and methods for their use
FI3724196T3 (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
IL258690A (en) Pyridone derivatives and their use as kinase inhibitors
EP3331536A4 (en) Compositions and methods for modulating abhd2 activity
GB201705201D0 (en) Novel compounds and their use as kinase inhibitors
GB201609580D0 (en) Novel compounds and their use as kinase inhibitors
GB201509381D0 (en) Novel compounds and their use as kinase inhibitors
GB201505460D0 (en) Novel compounds and their use as kinase inhibitors
AU2015903010A0 (en) Heterocyclic Compounds and Methods for their Use
AU2015902922A0 (en) Heterocyclic compounds and methods for their use
AU2015902886A0 (en) Heterocyclic Compounds And Methods For Their Use
AU2015902830A0 (en) Heterocyclic compounds and methods for their use
AU2015901751A0 (en) Heterocyclic Compounds And Methods For Their Use